New

Chrome Plugin Live! Redefine the way you read FinTwit 🚀 Install Now

You have successfully sign out
Loading...
Shape
Eterna Therapeutics Inc.
ERNA
Shape
US Flag

NASDAQ

Unprofitable

EPS improving

Unprofitable

EPS improving

5M

Biotechnology

Next Earning date - 11 Nov 2024

5M

Biotechnology

Next Earning date - 11 Nov 2024

0.95USD
Shape-0.02 ( -2.07%)
favorite-chart

Relative Strenght

68
favorite-chart

Volume Buzz

-5%
favorite-chart

Earning Acce

No
favorite-chart

Dist 52w H.

64%
OverviewChart

Quote Panel

Shape
Updated October 4, 2024
1W -9.53 % 1M -43.46 % 3M -49.20 % 1Y -54.98 %

Key Metrics

Shape

  • Market Cap

    5.14M

  • Shares Outstanding

    5.41M

  • Share in Float

    2.79M

  • Dividende

    0

  • Earning Date

    11 Nov 2024

  • Price Target

    0.9499

  • Average Volume

    24655

  • Beta

    7.843

  • Range

    0.84-2.63

  • Industry

    Biotechnology

  • Website

    https://www.brooklynitx.com

  • Sector

    Healthcare

Fundamentals

Shape

N/A

P/E Ratio

31.73x

P/S Ratio

-0.60x

P/B Ratio

-1.5

Debt/Equity

-14765.4%

Net Margin

$-4.4

EPS

How ERNA compares to sector?

P/E Ratio

ERNA

0x

RCUS -6x
CGEM -6x
ANNX -7x
GPCR -21x
RLAY -3x

Relative Strength

Shape

ERNA

Sector

loading...

Top 5 RS in Group

Symbol

Company

RS

5-Day Perf.

Forecast

Shape

$33M

Shape69713%

2025-Revenue

$10.80

Shape-959%

2025-EPS

$14M

Shape416%

2025-EBITDA

Analyst rating

No Data Available

Last analyst upgrade/downgrade

No Data Available

Earnings GrowthShape

status-upYoY

Current

Estimates

Q2.22

arrow
arrow

N/A

-1.20
vs -4.75

Q3.22

arrow
arrow

N/A

-2.49
vs -2.20

Q4.22

arrow
arrow

N/A

-1.24
vs -3.25

Q1.23

arrow
arrow

N/A

-1.06
vs -3.40

Q2.23

arrow
arrow

N/A

-0.85
vs -1.20

Q3.23

arrow
arrow

N/A

-1.03
vs -2.49

Q4.23

arrow
arrow

N/A

-1.14
vs -1.24

Q1.24

arrow
arrow

N/A

-1.23
vs -1.06

Q2.24

arrow
arrow

N/A

-1.02
vs -0.85

Q3.24

arrow
arrow

+250%

1.54
vs -1.03

Sales GrowthShape

status-upYoY

Current

Estimates

Q2.22

arrow
arrow

NA

NA  vs NA

Q3.22

arrow
arrow

NA

NA  vs NA

Q4.22

arrow
arrow

NA

NA  vs NA

Q1.23

arrow
arrow

NA

NA  vs NA

Q2.23

arrow
arrow

NA

NA  vs NA

Q3.23

arrow
arrow

NA

51K  vs NA

Q4.23

arrow
arrow

NA

17K  vs NA

Q1.24

arrow
arrow

NA

47K  vs NA

Q2.24

arrow
arrow

NA

47K  vs NA

Q3.24

arrow
arrow

-14%

43.7K  vs 51K

Return on EquityShape

status-upQoQ

Q3.22

arrow
arrow

-83%

-0.83
vs 0.48

Q4.22

arrow
arrow

-37%

-0.37
vs -0.83

Q1.23

arrow
arrow

-73%

-0.73
vs -0.37

Q2.23

arrow
arrow

-117%

-1.17
vs -0.73

Q3.23

arrow
arrow

-157%

-1.57
vs -1.17

Q4.23

arrow
arrow

-276%

-2.76
vs -1.57

Q1.24

arrow
arrow

+195%

1.95
vs -2.76

Q2.24

arrow
arrow

+65%

0.65
vs 1.95

Institutionnal OwnershipShape

status-up

Earnings Growth

Latest News

ERNA

globenewswire.com

8 hours ago

Eterna Therapeutics to Present at the ASGCT 27th Annual Meeting on Development of Beta 2 Microglobulin-Knockout (B2M-KO) iMSC Line with Enhanced Immunosuppressive Activity and Stealthing Features that May Further Augment the Therapeutic Potential of MSCs in Inflammatory Diseases
ERNA

globenewswire.com

8 hours ago

Eterna Therapeutics Announces the Appointment of Peter Cicala, JD, to its Board of Directors
ERNA

globenewswire.com

9 hours ago

Eterna Therapeutics Announces Appointment of Mahendra Rao, PhD, to its Scientific Advisory Board
ERNA

globenewswire.com

16 hours ago

Eterna Therapeutics Grants New President and CEO Sanjeev Luther Inducement Award Under Nasdaq Listing Rule 5635 (c)(4)
ERNA

globenewswire.com

16 hours ago

Eterna Therapeutics Names Sanjeev Luther as President and Chief Executive Officer
ERNA

globenewswire.com

18 hours ago

Eterna Therapeutics Announces $9.2 Million Convertible Debt and Warrant Financing

New Feature Coming Soon, Stay Tuned!

ShapeShape